FDA AdCom materials posted

RNS Number : 1570Q

AstraZeneca PLC

03 April 2009

 



FDA ADVISORY COMMITTEE DOCUMENTS FOR SEROQUEL XR AVAILABLE ON ASTRAZENECA WEB SITE

AstraZeneca is aware that earlier today, the US Food and Drug Administration (FDA) posted to its web site - and subsequently removed - briefing documents for the 8 April 2009 Psychopharmacologic Drugs Advisory Committee (PDAC) meeting. The PDAC meeting is scheduled to discuss the safety and efficacy data provided in supplemental new drug applications (sNDA) for SEROQUEL XR proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). 

AstraZeneca understands that some people accessed these documents before they were removed from the FDA site. To ensure that all investors have access to the information contained in the previously released FDA briefing materials, the company has now posted these documents, along with the AstraZeneca briefing documents, to its web site. 

A link can be found on the AstraZeneca homepage at www.astrazeneca.com

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com

Media Enquiries UK:
Chris Sampson	[phone] (24 hours)
Neil McCrae	[phone] (24 hours)
Sarah Lindgreen	[phone] (24 hours)
Investor Enquiries UK:
Jonathan Hunt	[phone]	mob: [phone]
Karl Hard	[phone]	mob: [phone]
Investor Enquiries US:
Ed Seage	[phone]	mob: [phone]
Jorgen Winroth	[phone]	mob: [phone]

3 April 2009

- ENDS -

 

END

 

 

MSCUORBRKWRSRAR